Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management released its second-quarter 2026 investor letter for Global Equity Strategy, highlighting Cytokinetics, Incorporated (NASDAQ:CYTK) as an addition to their portfolio. The biopharmaceutical company is developing muscle activators and inhibitors for treating debilitating diseases, with FDA approval for Myqorzo, a treatment for hypertrophic cardiomyopathy.

Myqorzo is considered superior to Bristol Myers Squibb's Camzyos due to better symptom relief and simpler dosing. Polaris acknowledged the potential of Cytokinetics but believes AI stocks offer greater upside potential and less downside risk. The company's stock closed at $67.59 per share on September 22, 2026, with a 52-week range of $47.22 to $88.31.